Arkolith/Insider Trading/TALS/Form 4/A

Ildstad Suzanne

DirectorTalaris Therapeutics, Inc. (TALS) · full profile →Form 4/A · filed Apr 7, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$13K
Net Open-Market Flow
-$13K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 17, 2023Sell(S)4K$2.05$7K3.1M
Feb 16, 2023Sell(S)3K$2.06$6K3.1M

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001209191-23-023778) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML